Sigachi Indust. (SIGACHI)
TurnaroundFairStock Score: 43/100 — MIXED
Score breakdown: P/E: 2/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹27.28 |
| Market Cap | ₹1,043.42 Cr |
| P/E Ratio | 19.21 |
| ROCE | 15.54% |
| ROE | -17.28% |
| Dividend Yield | 0.37% |
| Profit Growth | 108.21% |
| Debt/Equity | 0.31 |
| Sales Growth | 5.53% |
| Promoter Holding | 39.7% |
| 52-Week Range | ₹16.65 — ₹40.8 |
| Sector | Pharmaceuticals & Biotechnology |
| Book Value | ₹13.54 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
When I look at Sigachi, I see a business that fails Graham's first test: a consistent earnings record. The numbers here are loud warning bells. Sales have fallen nearly 16%, and profit growth has collapsed by more than 96% — from an already modest base to almost nothing. The latest quarter reports net profit of roughly ₹0 Cr on ₹117 Cr of sales, which tells me the margin structure has broken down. A negative ROE of -17.28% means shareholder capital is shrinking, despite a positive ROCE of 15.54%. That gap suggests operating assets still earn something, but the equity returns are being destroyed somewhere in the capital structure or by non-operating items. In Buffett's language, the economic moat is missing or under serious attack.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer